Histogen Inc. stock is up 94.12% since 30 days ago. The next earnings date is Mar 15, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 75% of the previous 3 March’s closed higher than February.
Histogen Inc. focuses on developing hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee. The company also offers Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!